Acarbose is not appreciably absorbed following oral administration. Bioavailability of the parent drug is only 1% to 2%. Metabolites formed in the intestine by either bacteria or enzymatic hydrolysis are subsequently absorbed and account for 35% of an oral dose. These metabolites are not known to possess pharmacological activity or toxicity.
Following intravenous acarbose administration (not commercially available), 90% of a dose is recovered in the urine as acarbose. The plasma elimination half-life of acarbose activity (including metabolites) is approximately 2 h. There is no accumulation during long term use in patients with normal renal function. In renal impairment (creatinine clearance less than 25 mL/min), accumulation produces peak serum acarbose concentrations five times higher than norma. However, considering that bioavailability is minimal, this accumulation would not likely be clinically significant. Your most trusted pharmacy offering purchase alegra and giving you very fast shipping.
In Canada, acarbose (Prandase; Bayer) is approved as an adjunct to the prescribed diet for NIDDM patients who have failed to achieve adequate control with non pharmacological management (diet and exercise). The official indications state that “Prandase should be considered as complementary to dietary therapy and physical exercise before resorting to other forms of treatment, such as oral hypoglycemics”. In the United States, where it is marketed as Precose (Bayer), acar-bose is also approved for “use in combination with oral hypoglycemics if additional glycemic control is desired”.